The daraxonrasib FDA filing is nearing completion, marking a pivotal regulatory moment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Revolution Medicines announced on 7 July 2026 that its rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration is approaching its final stages, while the European Medicines Agency has simultaneously begun a phased review of the drug. If approved, daraxonrasib would become the first targeted therapy to demonstrate an overall survival benefit in a broad population of pancreatic cancer patients, marking the most significant treatment advance for this disease in over a decade.
The regulatory momentum behind daraxonrasib reflects the scale of the clinical data underpinning it. The Phase 3 RASolute 302 trial, published in the New England Journal of Medicine and presented to a standing ovation at the 2026 American Society of Clinical Oncology Annual Meeting, demonstrated a 60 per cent reduction in the risk of death compared with standard chemotherapy, nearly doubling median overall survival from 6.7 months to 13.2 months in the overall intent-to-treat population.
How the Daraxonrasib FDA Filing Is Being Accelerated
Revolution Medicines is submitting its NDA through a rolling submission process under the FDA Commissioner’s National Priority Voucher (CNPV) pilot programme, an accelerated review pathway launched in June 2025. The CNPV programme was designed to reduce review timelines for drug applications aligned with critical United States national health priorities from the standard 10 to 12 months to a target of one to two months from filing to action.
Daraxonrasib was selected for the CNPV programme and granted a national priority voucher in October 2025. The drug has also received Breakthrough Therapy Designation from the FDA for the treatment of patients with previously treated metastatic PDAC harbouring G12 mutations, as well as Orphan Drug Designation for the treatment of pancreatic cancer. These designations collectively signal the agency’s recognition of a significant unmet medical need and the strength of the supporting clinical evidence.
The speed at which the CNPV pathway has delivered approvals to date offers a useful benchmark. In its first year, the programme approved products in as few as 44 days after NDA filing. The CNPV programme remains a pilot, and the FDA held a public hearing in June 2026 to gather stakeholder feedback on eligibility criteria, review procedures, and programme implementation.
The Clinical Evidence Driving the Filing
The daraxonrasib FDA filing is supported by results from the global, randomised Phase 3 RASolute 302 trial, which enrolled 500 patients with previously treated metastatic PDAC across North America, Europe, and Asia. Patients were randomised to receive either oral daraxonrasib at 300 mg once daily or investigator’s choice of intravenous chemotherapy.
In the dual primary analysis population of patients with RAS G12 mutations, daraxonrasib reduced the risk of death by 60 per cent compared with chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). Median progression-free survival was 7.3 months versus 3.5 months, and the objective response rate was 33.2 per cent compared with 11.8 per cent with chemotherapy. The trial met all primary and key secondary endpoints. The benefit was most clearly established in patients with RAS G12 mutations, who made up approximately 92 per cent of the trial population. Among the small subgroup of 41 patients with non-G12 RAS mutations, the overall survival hazard ratio still favoured daraxonrasib, but progression-free survival in this subgroup numerically favoured chemotherapy, a finding that should be interpreted with caution given the limited sample size. It is also notable that 15.1 per cent of patients randomised to chemotherapy did not receive treatment, most by patient choice, a factor that may have influenced the overall survival comparison.
The safety data further strengthened the regulatory case. Grade 3 or higher treatment-related adverse events occurred in 43.6 per cent of patients receiving daraxonrasib versus 57.5 per cent in the chemotherapy group. Critically, treatment discontinuation due to adverse events was 1.2 per cent with daraxonrasib compared with 11.2 per cent with chemotherapy. The most common side effects leading to dose reduction were rash and stomatitis. Patients treated with daraxonrasib also reported significantly delayed deterioration in cancer-related pain and global quality of life.
Brian Wolpin, Professor of Medicine at Harvard Medical School, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, and principal investigator for RASolute 302, stated:
“This is the first RAS inhibitor evaluated in a large, randomised trial for patients with pancreatic cancer, and it demonstrates how important an impact these novel medicines are likely to have on the treatment of the disease.”
Rachna Shroff, Chief of the Division of Haematology/Oncology at the University of Arizona Cancer Center and an ASCO expert in gastrointestinal cancers, described the findings as proof that targeting KRAS in pancreatic cancer is both feasible and effective, calling the results a potential new standard of care in the second-line setting.
What the EMA Phased Review Means for Global Access
Alongside the daraxonrasib FDA filing in the United States, Revolution Medicines announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has started a phased review of daraxonrasib. A phased review allows the regulator to assess clinical data in stages as it becomes available, ahead of a full marketing authorisation application, with the aim of accelerating the assessment timeline.
Daraxonrasib has been designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognised as a high priority under the EMA’s Cancer Medicines Pathfinder project. Revolution Medicines has stated that it continues to engage with regulatory authorities around the world as it prepares submissions in additional territories. For patients in the UK and Europe, the practical path from EMA phased review to marketing authorisation and subsequent national reimbursement decisions is likely to extend well beyond any US approval timeline, and no specific European access date has been indicated.
Expanded Access Already Under Way
While the regulatory review process continues, patients with previously treated metastatic PDAC in the United States already have a route to access daraxonrasib through an expanded access treatment protocol (EAP). On 30 April 2026, the FDA signed a “safe to proceed” letter for Revolution Medicines, authorising the EAP just two days after the company submitted its application on 28 April. The decision was publicly announced on 1 May 2026.
The expanded access programme is available to patients who cannot participate in a clinical trial and whose treating physician submits a request to Revolution Medicines on their behalf. The programme requires RAS mutation testing for stratification and is designed to provide treatment access in a controlled, monitored setting consistent with FDA regulations for investigational medicines.
Why This Matters for Pancreatic Cancer Patients
Pancreatic cancer remains one of the most lethal malignancies in oncology. According to American Cancer Society data published in January 2026, the five-year relative survival rate for all stages combined is 13 per cent, the lowest among major cancers. For patients with distant metastatic disease, that figure falls to approximately 3 per cent. An estimated 67,530 Americans will be diagnosed with pancreatic cancer in 2026, and approximately 52,740 are expected to die from the disease, making it the third leading cause of cancer-related death in the United States.
More than 90 per cent of PDAC tumours harbour RAS mutations, making RAS one of the most pervasive oncogenic drivers in this disease. For decades, RAS was considered “undruggable.” Earlier KRAS-targeting drugs, including sotorasib and adagrasib, were approved for lung cancer but targeted only the rare G12C mutation, which accounts for fewer than 2 per cent of pancreatic cancer cases. Daraxonrasib takes a fundamentally different approach. As a RAS(ON) multi-selective inhibitor, it targets the active, GTP-bound state of RAS across multiple mutation variants, including G12, G13, and Q61, as well as wild-type RAS. This broad mechanism means it is potentially relevant to the vast majority of PDAC patients.
Before RASolute 302, only one positive randomised trial in this treatment setting had been reported in more than a decade: the study of 5-FU plus nanoliposomal irinotecan, which offered median overall survival of approximately 6 to 6.5 months. Daraxonrasib has effectively doubled that benchmark while offering a better-tolerated, oral alternative to intravenous chemotherapy. Revolution Medicines has not yet disclosed pricing for daraxonrasib. For a drug that would replace relatively low-cost generic chemotherapy regimens, the price point and payer coverage decisions will be critical factors in determining how broadly the survival benefit demonstrated in RASolute 302 translates into real-world patient access.
The Broader Pipeline and What Comes Next
Revolution Medicines is not limiting daraxonrasib to the second-line metastatic setting. The company is advancing two additional Phase 3 registrational trials in PDAC. RASolute 303 is a three-arm study evaluating daraxonrasib as monotherapy and in combination with gemcitabine and nab-paclitaxel versus chemotherapy alone as first-line treatment for metastatic pancreatic cancer. The trial began dosing patients in April 2026 and is being led by Dr Wolpin at Dana-Farber. RASolute 304 is evaluating adjuvant daraxonrasib versus observation following surgery and chemotherapy in patients with resected PDAC, with the first patient randomised in December 2025.
If the daraxonrasib FDA filing results in approval under the CNPV programme’s accelerated timeline, it could reach patients in the United States before the end of 2026 or early 2027. For a disease that has seen so few treatment advances over so many years, the pace of regulatory engagement reflects the strength of the clinical evidence and the scale of the unmet need.
